首页 > 最新文献

Ayu最新文献

英文 中文
Comparative evaluation of a modified endodontic approach using Curcuma longa L. and conventional pulpectomy in primary molars: A randomized clinical trial. 一项随机临床试验对使用姜黄和常规乳牙牙髓切除术的改良根管治疗方法的比较评价。
Ayu
Pub Date : 2021-07-01 Epub Date: 2023-04-12 DOI: 10.4103/ayu.AYU_12_20
Putta Sai Sahiti, Rekhalakshmi Kamatham

Background: Turmeric (Curcuma longa) is known for its anti-inflammatory and anti-septic properties.

Aim: The aim is to compare a modified endodontic approach using turmeric and conventional Metapex® pulpectomy in primary molars.

Materials and methods: Thirty children, in the age range of 4-9 years, with at least one primary mandibular molar indicated for pulpectomy, were included. Teeth were randomly assigned to turmeric and Metapex® groups. For those that were assigned to turmeric, after coronal and radicular pulp extirpation, a freshly prepared paste of turmeric powder and methyl cellulose (2:1) with saline was packed in the coronal pulp chamber. In the Metapex® group, a conventional pulpectomy was performed. Clinical and radiographic success was recorded at 3-, 6-, and 12-month follow-up visits. The data was statistically analyzed using the Chi-square test.

Results: There were no clinical and radiographic failures at 3- and 6-month visits in both groups. The 12-month evaluation revealed clinical success rates of 92% (12 out of 13) and 100% (14 out of 14) for turmeric and Metapex®, respectively, whereas, the radiographic success rates were 85% (12 out of 13) for turmeric and 93% (13 out of 14) for Metapex®. No statistically significant differences were found between the groups at different follow-ups (P > 0.05).

Conclusions: A modified endodontic approach using turmeric and conventional Metapex® pulpectomy did not differ significantly in total success after 12 months.

背景:姜黄(Curcuma longa)以其抗炎和抗败血症的特性而闻名。目的:比较使用姜黄和传统Metapex®乳牙牙髓切除术的改良牙髓治疗方法。材料和方法:纳入30名年龄在4-9岁之间的儿童,他们至少有一个下颌原发磨牙需要进行牙髓切除术。将牙齿随机分为姜黄组和Metapex®组。对于那些被分配给姜黄的患者,在冠髓和根髓摘除后,将新制备的姜黄粉末和甲基纤维素(2:1)与盐水的糊状物填充在冠髓室中。Metapex®组进行了传统的牙髓切除术。在3个月、6个月和12个月的随访中记录了临床和放射学的成功。使用卡方检验对数据进行统计分析。结果:两组在第3个月和第6个月就诊时均未出现临床和放射学失败。12个月的评估显示,姜黄和Metapex®的临床成功率分别为92%(12/13)和100%(14/14),而姜黄的放射学成功率为85%(12/13。在不同的随访中,两组之间没有发现统计学上的显著差异(P>0.05)。结论:使用姜黄和传统Metapex®牙髓切除术的改良牙髓治疗方法在12个月后的总成功率没有显著差异。
{"title":"Comparative evaluation of a modified endodontic approach using <i>Curcuma longa</i> L. and conventional pulpectomy in primary molars: A randomized clinical trial.","authors":"Putta Sai Sahiti,&nbsp;Rekhalakshmi Kamatham","doi":"10.4103/ayu.AYU_12_20","DOIUrl":"10.4103/ayu.AYU_12_20","url":null,"abstract":"<p><strong>Background: </strong>Turmeric (<i>Curcuma longa</i>) is known for its anti-inflammatory and anti-septic properties.</p><p><strong>Aim: </strong>The aim is to compare a modified endodontic approach using turmeric and conventional Metapex<sup>®</sup> pulpectomy in primary molars.</p><p><strong>Materials and methods: </strong>Thirty children, in the age range of 4-9 years, with at least one primary mandibular molar indicated for pulpectomy, were included. Teeth were randomly assigned to turmeric and Metapex<sup>®</sup> groups. For those that were assigned to turmeric, after coronal and radicular pulp extirpation, a freshly prepared paste of turmeric powder and methyl cellulose (2:1) with saline was packed in the coronal pulp chamber. In the Metapex<sup>®</sup> group, a conventional pulpectomy was performed. Clinical and radiographic success was recorded at 3-, 6-, and 12-month follow-up visits. The data was statistically analyzed using the Chi-square test.</p><p><strong>Results: </strong>There were no clinical and radiographic failures at 3- and 6-month visits in both groups. The 12-month evaluation revealed clinical success rates of 92% (12 out of 13) and 100% (14 out of 14) for turmeric and Metapex<sup>®</sup>, respectively, whereas, the radiographic success rates were 85% (12 out of 13) for turmeric and 93% (13 out of 14) for Metapex<sup>®</sup>. No statistically significant differences were found between the groups at different follow-ups (<i>P</i> > 0.05).</p><p><strong>Conclusions: </strong>A modified endodontic approach using turmeric and conventional Metapex<sup>®</sup> pulpectomy did not differ significantly in total success after 12 months.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/af/AYU-42-130.PMC10251285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Add-on effect of Ayurvedic treatment protocol for diabetic retinopathy: A randomized controlled clinical study. 阿育吠陀治疗糖尿病视网膜病变的附加效果:一项随机对照临床研究。
Ayu
Pub Date : 2021-07-01 Epub Date: 2023-04-12 DOI: 10.4103/ayu.AYU_208_19
V Krishna Kumar, B Vaghela Dharmendra Singh, Rajagopala Manjusha

Background: Diabetic retinopathy (DR), the leading cause of visual disability in diabetics, is a significant complication of diabetes mellitus. Currently available conventional treatments for DR have certain limitations, considering which Ayurvedic treatment protocol was designed.

Aim: The aim of this study was to evaluate the clinical efficacy of the Ayurvedic treatment protocol for DR.

Materials and methods: This was a randomized, controlled, black box design clinical study conducted from April 2016 to September 2017 by the department of Shalakya Tantra of a tertiary academic hospital in Western India. A hundred patients of DR in the age group 30-70 years were randomly divided into two groups by simple random sampling using computer-generated random number tables. In the trial group (n = 70), the preparatory phase included Dipana-Pachana (stomachic and digestant), Koshtha Shodhana (mild therapeutic purgation), and Shiro Virechana (eliminative nasal medication). The treatment phase included Marsha Nasya (nasal medication) and Pratimarsha Nasya (nasal medication of mild dose) with Durvadi Ghrita, Takra Dhara (pouring medicated buttermilk over the scalp) with Siddha Takra, and intake of Rasayana Yoga (treatment duration - 3 months). In the control group (n = 30), patients were kept under conservative treatment and observed during the trial period of 3 months. Patients of both groups continued with their treatment for diabetes and DR if any. Two follow-ups were done at an interval of 15 days. The primary outcomes were objective signs like best-corrected visual acuity (BCVA); ophthalmoscopic signs such as superficial hemorrhages, dot-blot hemorrhages, hard exudates, cotton wool spots, neovascularization disc, neovascularization elsewhere, and fibrovascular proliferation; subjective symptoms such as diminished vision, blurred vision, frequent changes in presbyopia glasses, perception of flashes of light, floaters, and problem for dark adaptation. The secondary outcomes were fasting blood sugar (FBS), postprandial blood sugar (PPBS), urine sugar, serum cholesterol, hemoglobin (Hb), glycosylated HbA1C, liver function test, and renal function test outcomes were assessed before and after the treatment.

Results: Ninety participants were included in the analysis of the primary outcome (62 in the trial and 28 in the control group). The trial group provided better results which were statistically significant on dot-blot hemorrhages, superficial hemorrhages, hard exudates, BCVA, FBS, and serum cholesterol. Both the groups provided almost similar effects in PPBS, Hb, HbA1C, and urine sugar which were statistically insignificant. Adverse effects were not reported in any of the patient among either groups.

Conclusion: Ayurvedic treatment protocol is safe and effective in DR.

背景:糖尿病视网膜病变(DR)是糖尿病患者视力残疾的主要原因,也是糖尿病的重要并发症。考虑到阿育吠陀治疗方案的设计,目前可用的DR常规治疗有一定的局限性。目的:本研究的目的是评估阿育吠陀治疗DR的临床疗效。材料和方法:这是一项随机、对照、黑匣子设计的临床研究,由印度西部一家三级学术医院的Shalakya Tantra部门于2016年4月至2017年9月进行。使用计算机生成的随机数表,通过简单的随机抽样将100名30-70岁年龄组的DR患者随机分为两组。在试验组(n=70)中,准备阶段包括Dipana Pachana(胃和消化剂)、Koshtha Shodhana(轻度治疗性通便)和Shiro Virechana(消除鼻腔药物)。治疗阶段包括Marsha Nasya(鼻腔药物)和Pratimarsha Nasya(轻度鼻腔药物)与Durvadi Ghrita,Takra Dhara(将药物酪乳浇在头皮上)与Siddha Takra,以及接受Rasayana瑜伽(治疗持续时间-3个月)。在对照组(n=30)中,患者接受保守治疗,并在3个月的试验期间进行观察。两组患者继续进行糖尿病和DR的治疗(如果有的话)。两次随访间隔15天。主要结果是客观症状,如最佳矫正视力(BCVA);眼科体征,如浅表出血、斑点出血、硬渗出物、棉絮斑点、新生血管盘、其他地方的新生血管和纤维血管增生;主观症状,如视力下降、视力模糊、老花镜频繁更换、对闪光的感知、漂浮物和暗适应问题。次要结果是空腹血糖(FBS)、餐后血糖(PPBS)、尿糖、血清胆固醇、血红蛋白(Hb)、糖化血红蛋白(HbA1C)、肝功能测试和肾功能测试。在治疗前后评估结果。结果:90名参与者被纳入主要结果分析(试验组62名,对照组28名)。试验组提供了更好的结果,在斑点印迹出血、浅表出血、硬渗出物、BCVA、FBS和血清胆固醇方面具有统计学意义。两组在PPBS、Hb、HbA1C和尿糖方面的效果几乎相似,但在统计学上不显著。两组患者均未报告不良反应。结论:阿育吠陀治疗DR安全有效。
{"title":"Add-on effect of Ayurvedic treatment protocol for diabetic retinopathy: A randomized controlled clinical study.","authors":"V Krishna Kumar,&nbsp;B Vaghela Dharmendra Singh,&nbsp;Rajagopala Manjusha","doi":"10.4103/ayu.AYU_208_19","DOIUrl":"10.4103/ayu.AYU_208_19","url":null,"abstract":"<p><strong>Background: </strong>Diabetic retinopathy (DR), the leading cause of visual disability in diabetics, is a significant complication of diabetes mellitus. Currently available conventional treatments for DR have certain limitations, considering which Ayurvedic treatment protocol was designed.</p><p><strong>Aim: </strong>The aim of this study was to evaluate the clinical efficacy of the Ayurvedic treatment protocol for DR.</p><p><strong>Materials and methods: </strong>This was a randomized, controlled, black box design clinical study conducted from April 2016 to September 2017 by the department of Shalakya Tantra of a tertiary academic hospital in Western India. A hundred patients of DR in the age group 30-70 years were randomly divided into two groups by simple random sampling using computer-generated random number tables. In the trial group (<i>n</i> = 70), the preparatory phase included <i>Dipana-Pachana</i> (stomachic and digestant), <i>Koshtha Shodhana</i> (mild therapeutic purgation), and <i>Shiro Virechana</i> (eliminative nasal medication). The treatment phase included <i>Marsha Nasya</i> (nasal medication) and <i>Pratimarsha Nasya</i> (nasal medication of mild dose) with <i>Durvadi Ghrita</i>, <i>Takra Dhara</i> (pouring medicated buttermilk over the scalp) with <i>Siddha Takra</i>, and intake of <i>Rasayana Yoga</i> (treatment duration - 3 months). In the control group (<i>n</i> = 30), patients were kept under conservative treatment and observed during the trial period of 3 months. Patients of both groups continued with their treatment for diabetes and DR if any. Two follow-ups were done at an interval of 15 days. The primary outcomes were objective signs like best-corrected visual acuity (BCVA); ophthalmoscopic signs such as superficial hemorrhages, dot-blot hemorrhages, hard exudates, cotton wool spots, neovascularization disc, neovascularization elsewhere, and fibrovascular proliferation; subjective symptoms such as diminished vision, blurred vision, frequent changes in presbyopia glasses, perception of flashes of light, floaters, and problem for dark adaptation. The secondary outcomes were fasting blood sugar (FBS), postprandial blood sugar (PPBS), urine sugar, serum cholesterol, hemoglobin (Hb), glycosylated HbA1C, liver function test, and renal function test outcomes were assessed before and after the treatment.</p><p><strong>Results: </strong>Ninety participants were included in the analysis of the primary outcome (62 in the trial and 28 in the control group). The trial group provided better results which were statistically significant on dot-blot hemorrhages, superficial hemorrhages, hard exudates, BCVA, FBS, and serum cholesterol. Both the groups provided almost similar effects in PPBS, Hb, HbA1C, and urine sugar which were statistically insignificant. Adverse effects were not reported in any of the patient among either groups.</p><p><strong>Conclusion: </strong>Ayurvedic treatment protocol is safe and effective in DR.</","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/92/AYU-42-118.PMC10251286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An observational study on acceptability, palatability, and safety of Ayurveda immunity booster kit for the prevention of COVID-19 in frontline workers in Jaipur, India. 一项关于印度斋浦尔一线工作人员使用阿育吠陀免疫增强试剂盒预防新冠肺炎的可接受性、适口性和安全性的观察性研究。
Ayu
Pub Date : 2021-07-01 Epub Date: 2023-04-12 DOI: 10.4103/ayu.ayu_16_22
Sarvesh Kumar Singh, Kshipra Rajoria, Sanjeev Sharma, Pawan Kumar Godatwar, Suman Sharma, Mita Kotecha, Sarvesh Kumar Agrawal, Rajendra Prasad Sharma, Shobhnath Yadav, Ramkishor Joshi

Background: National Institute of Ayurveda, Jaipur, India, had distributed Ayurveda immunity booster kit (AIBK) (prepared at own pharmacy and comprising Chyawanprasha - 300 g, Vyadhi Kshamatva Kwatha - 300 g, and Vyadhi Kshamatva capsule - 30 g) for 15 days among the health-care workers, sanitation workers, and security and police staff engaged in the containment zones for prevention of COVID-19.

Aim: The aim of present study was to explore the medication that may be effective in prevention of the COVID -19. Hence, this study was done to assess the compliance of these medicines and their effects in the prevention of COVID-19.

Methods: One thousand seven hundred and fourteen frontline workers were provided with the AIBK for 15 days from April 24, 2020, to June 27, 2020. Data of frontline workers who had participated in AIBK and completed the treatment regimen with 2 weeks of follow-up after treatment with complete available data for safety, palatability, efficacy, and compliance were included in the study. Any adverse event needing hospitalization or medication, drug compliance and palatability, and appearance of the symptoms of COVID-19 or testing positive for COVID-19 were the outcome measures.

Results: Out of 1714 participants, 1003 participants were found to be eligible for this analysis. The median age of these participants was 39 years (range, 19-70), and males accounted for 90.1% (904 of 1003). A total of 7.5% of participants (75 of 1003) reported having adverse events after taking the study treatment. None of the participants reported any serious adverse effects after the administration of the AIBK. The acceptability of the AIBK was as high as 97.4%. None of the participants reported positive for COVID-19 results or COVID-19 symptoms up to 2 weeks of follow-up after completion of the study treatment.

Conclusion: The acceptability of AIBK is good and indicates its role in the prevention of COVID-19-like illness, hence further randomized control trials or cohort studies can be done to assess the mechanism of action and efficacy of AIBK as the preventive strategy in COVID-19.

背景:印度斋浦尔国家阿育吠陀研究所向医护人员、环卫工人、,以及参与新冠肺炎预防控制区的安全和警察工作人员。Aim:本研究的目的是探索可能有效预防新冠肺炎的药物。因此,本研究旨在评估这些药物的依从性及其在预防COVID-19中的效果。方法:从2020年4月24日至2020年6月27日,一千七百一十四名一线工作人员接受了为期15天的AIBK。研究中包括了参与AIBK并在治疗后2周随访完成治疗方案的一线工作人员的数据,这些工作人员的安全性、适口性、疗效和依从性都有完整的可用数据。任何需要住院治疗或药物治疗的不良事件、药物依从性和适口性、出现新冠肺炎症状或新冠肺炎检测呈阳性均为结果指标。结果:在1714名参与者中,1003名参与者符合此分析的条件。这些参与者的中位年龄为39岁(19-70岁),男性占90.1%(1003人中有904人)。共有7.5%的参与者(1003人中的75人)报告在接受研究治疗后出现不良事件。没有一名参与者在服用AIBK后报告任何严重的不良反应。AIBK的可接受性高达97.4%。在研究治疗完成后2周的随访中,没有任何参与者报告新冠肺炎结果或新冠肺炎症状呈阳性。结论:AIBK的可接受性良好,表明其在预防新冠肺炎样疾病中的作用,因此可以进行进一步的随机对照试验或队列研究,以评估AIBK作为新冠肺炎预防策略的作用机制和疗效。
{"title":"An observational study on acceptability, palatability, and safety of <i>Ayurveda</i> immunity booster kit for the prevention of COVID-19 in frontline workers in Jaipur, India.","authors":"Sarvesh Kumar Singh,&nbsp;Kshipra Rajoria,&nbsp;Sanjeev Sharma,&nbsp;Pawan Kumar Godatwar,&nbsp;Suman Sharma,&nbsp;Mita Kotecha,&nbsp;Sarvesh Kumar Agrawal,&nbsp;Rajendra Prasad Sharma,&nbsp;Shobhnath Yadav,&nbsp;Ramkishor Joshi","doi":"10.4103/ayu.ayu_16_22","DOIUrl":"10.4103/ayu.ayu_16_22","url":null,"abstract":"<p><strong>Background: </strong>National Institute of Ayurveda, Jaipur, India, had distributed <i>Ayurveda</i> immunity booster kit (AIBK) (prepared at own pharmacy and comprising <i>Chyawanprasha -</i> 300 g, <i>Vyadhi Kshamatva Kwatha</i> - 300 g, and <i>Vyadhi Kshamatva</i> capsule - 30 g) for 15 days among the health-care workers, sanitation workers, and security and police staff engaged in the containment zones for prevention of COVID-19.</p><p><strong>Aim: </strong>The aim of present study was to explore the medication that may be effective in prevention of the COVID -19. Hence, this study was done to assess the compliance of these medicines and their effects in the prevention of COVID-19.</p><p><strong>Methods: </strong>One thousand seven hundred and fourteen frontline workers were provided with the AIBK for 15 days from April 24, 2020, to June 27, 2020. Data of frontline workers who had participated in AIBK and completed the treatment regimen with 2 weeks of follow-up after treatment with complete available data for safety, palatability, efficacy, and compliance were included in the study. Any adverse event needing hospitalization or medication, drug compliance and palatability, and appearance of the symptoms of COVID-19 or testing positive for COVID-19 were the outcome measures.</p><p><strong>Results: </strong>Out of 1714 participants, 1003 participants were found to be eligible for this analysis. The median age of these participants was 39 years (range, 19-70), and males accounted for 90.1% (904 of 1003). A total of 7.5% of participants (75 of 1003) reported having adverse events after taking the study treatment. None of the participants reported any serious adverse effects after the administration of the AIBK. The acceptability of the AIBK was as high as 97.4%. None of the participants reported positive for COVID-19 results or COVID-19 symptoms up to 2 weeks of follow-up after completion of the study treatment.</p><p><strong>Conclusion: </strong>The acceptability of AIBK is good and indicates its role in the prevention of COVID-19-like illness, hence further randomized control trials or cohort studies can be done to assess the mechanism of action and efficacy of AIBK as the preventive strategy in COVID-19.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/26/AYU-42-111.PMC10251284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9992404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Haratala Shodhana in the therapeutic efficacy of Rasamanikya along with Guduchi Ghana in the treatment of Ekakushtha (psoriasis): A double-blind randomised clinical trial. Haratala Shodhana在Rasamanikya和Guduchi Ghana治疗Ekakushtha(银屑病)疗效中的作用:一项双盲随机临床试验。
Ayu
Pub Date : 2021-04-01 Epub Date: 2023-03-16 DOI: 10.4103/ayu.ayu_292_21
Dipali Narendrakumar Parekh, Dharmishtha Bopaliya, Dilipkumar Prajapati, Prashant Bedarkar, B J Patgiri

Introduction: Rasamanikya (RM) and Guduchi Ghana (GG) are well-known formulations for treating skin disorders in Ayurveda. The drug RM is prepared from Shuddha Haratala (processed orpiment) as a single ingredient. In the present study, RM was prepared from the Haratala, which was Shodhita, with two different media, viz., Kushmanda Swarasa and Churnodaka. In the classics, the preparation of RM is mentioned in the Kushmanda Shodhita Haratala. However, the availability and cost of Kushmanda are the main points of concern in the present era. Shodhana of Haratala by Churnodaka is more cost-effective than Kushmanda Swarasa.

Aim: The aim of this study is to evaluate the comparative efficacy of RM prepared by Churnodaka Shodhita Haratala (CSHRM) and RM prepared by Kushmanda Shodhita Haratala (KSHRM) with GG in Ekakustha (psoriasis).

Materials and methods: The study was a randomized double-blind study involving 76 patients with Ekakushtha that were randomly divided into two groups. Patients registered in group A (n = 37) were treated with CSHRM with GG (125 mg + 375 mg) and group B (n = 36) with KSHRM with GG (125 mg + 375 mg) for 8 weeks. The Wilcoxon signed rank test and paired t-test were applied to evaluate the effect of therapy in the individual group for subjective criteria like the PASI score, Matsyashakalopamam (looks like the scales of a fish), Rukshata (dryness), Aswedanam (anhydrosis), Daha (burning), Strava (discharge), Unnati (raised patches), Kandu (itching), Mahavastu (broad-based), and Vaivarnya (discoloration), while the comparison of results between the groups for the same was done by applying the Coefficient of Variation (CV).

Result: CSHRM with GG showed better results in all signs and symptoms except Matsyaskalopamam, Aswedanam, Strava, Mahavastu, Nindra and DLQI in terms of the coefficient of variation. In both groups, statistically highly significant (P > 0.001) improvement was found in the signs and symptoms of Ekakushtha. However, the difference between the groups was statistically nonsignificant.

Conclusion: Rasamanikya prepared with both media Shodhita Haratala along with Guduchi Ghana was discovered to be a safe and effective psoriasis treatment.

简介:Rasamanikya(RM)和Guduchi Ghana(GG)是阿育吠陀中治疗皮肤疾病的著名配方。药物RM是由Shuddha Haratala(加工雌黄)作为单一成分制备的。在本研究中,RM是用两种不同的介质,即Kushmanda Swarasa和Churnodaka,从Shodhita的Haratala制备的。在经典中,Kushmanda Shodhita Haratala中提到了RM的准备。然而,Kushmanda的可用性和成本是当今时代关注的主要问题。Churnodaka的Shodhana of Haratala比Kushmanda Swarasa更具成本效益。目的:本研究的目的是评估Churnodaka-Shodhita Haratala(CSHRM)和Kushman达·Shodhita哈拉塔拉(KSHRM)制备的RM与GG在Ekakustha(银屑病)中的比较疗效。材料和方法:该研究是一项随机双盲研究,涉及76名Ekakushtha患者将其随机分为两组。A组(n=37)的患者接受CSHRM加GG(125 mg+375 mg)治疗,B组(n=36)接受KSHRM加GG(125mg+375 mg.)治疗8周。根据主观标准,如PASI评分、Matsyashakalopamam(看起来像鱼的鳞片)、Rukshata(干燥)、Aswedanam(脱水)、Daha(烧伤)、Strava(出院)、Unnati(凸起的斑块)、Kandu(瘙痒)、Mahavastu(基础广泛)和Vaivarnya(变色),应用Wilcoxon符号秩检验和配对t检验来评估个体组的治疗效果,结果:CSHRM和GG在除Matsyaskalopam、Aswedanam、Strava、Mahavastu、Nindra和DLQI外的所有体征和症状方面均表现出较好的变异系数。在两组中,Ekakushtha的体征和症状均有统计学意义的显著改善(P>0.001)。然而,两组之间的差异在统计学上并不显著。结论:用Shodhita Haratala和Guduchi Ghana两种介质制备Rasamanikya是一种安全有效的银屑病治疗方法。
{"title":"Role of <i>Haratala Shodhana</i> in the therapeutic efficacy of <i>Rasamanikya</i> along with <i>Guduchi Ghana</i> in the treatment of <i>Ekakushtha</i> (psoriasis): A double-blind randomised clinical trial.","authors":"Dipali Narendrakumar Parekh,&nbsp;Dharmishtha Bopaliya,&nbsp;Dilipkumar Prajapati,&nbsp;Prashant Bedarkar,&nbsp;B J Patgiri","doi":"10.4103/ayu.ayu_292_21","DOIUrl":"10.4103/ayu.ayu_292_21","url":null,"abstract":"<p><strong>Introduction: </strong><i>Rasamanikya</i> (RM) and <i>Guduchi Ghana</i> (GG) are well-known formulations for treating skin disorders in <i>Ayurveda</i>. The drug RM is prepared from <i>Shuddha Haratala</i> (processed orpiment) as a single ingredient. In the present study, RM was prepared from the <i>Haratala</i>, which was <i>Shodhita</i>, with two different media, viz., <i>Kushmanda</i> <i>Swarasa</i> and <i>Churnodaka</i>. In the classics, the preparation of RM is mentioned in the <i>Kushmanda</i> <i>Shodhita</i> <i>Haratala</i>. However, the availability and cost of <i>Kushmanda</i> are the main points of concern in the present era. <i>Shodhana</i> of <i>Haratala</i> by <i>Churnodaka</i> is more cost-effective than <i>Kushmanda</i> <i>Swarasa</i>.</p><p><strong>Aim: </strong>The aim of this study is to evaluate the comparative efficacy of RM prepared by <i>Churnodaka Shodhita Haratala</i> (CSHRM) and RM prepared by <i>Kushmanda Shodhita Haratala</i> (KSHRM) with GG in <i>Ekakustha</i> (psoriasis).</p><p><strong>Materials and methods: </strong>The study was a randomized double-blind study involving 76 patients with <i>Ekakushtha</i> that were randomly divided into two groups. Patients registered in group A (n = 37) were treated with CSHRM with GG (125 mg + 375 mg) and group B (n = 36) with KSHRM with GG (125 mg + 375 mg) for 8 weeks. The Wilcoxon signed rank test and paired t-test were applied to evaluate the effect of therapy in the individual group for subjective criteria like the PASI score, <i>Matsyashakalopamam</i> (looks like the scales of a fish), <i>Rukshata</i> (dryness), <i>Aswedanam</i> (anhydrosis), <i>Daha</i> (burning), <i>Strava</i> (discharge), <i>Unnati</i> (raised patches), <i>Kandu</i> (itching), <i>Mahavastu</i> (broad-based), and <i>Vaivarnya</i> (discoloration), while the comparison of results between the groups for the same was done by applying the Coefficient of Variation (CV).</p><p><strong>Result: </strong>CSHRM with GG showed better results in all signs and symptoms except <i>Matsyaskalopamam</i>, <i>Aswedanam</i>, <i>Strava</i>, <i>Mahavastu</i>, <i>Nindra</i> and DLQI in terms of the coefficient of variation. In both groups, statistically highly significant (P > 0.001) improvement was found in the signs and symptoms of <i>Ekakushtha</i>. However, the difference between the groups was statistically nonsignificant.</p><p><strong>Conclusion: </strong><i>Rasamanikya</i> prepared with both media <i>Shodhita</i> <i>Haratala</i> along with <i>Guduchi Ghana</i> was discovered to be a safe and effective psoriasis treatment.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/c9/AYU-42-76.PMC10158648.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dhatri Lauha in the management of iron deficiency anemia: A prospective open-label single-arm multi-center trial. Dhatri-Lauha治疗缺铁性贫血:一项前瞻性开放标签单臂多中心试验。
Ayu
Pub Date : 2021-04-01 Epub Date: 2023-03-16 DOI: 10.4103/ayu.ayu_379_21
Narayanam Srikanth, Bhogavalli Chandrasekhara Rao, Babita Yadav, Amit Kumar Rai, Sophia Jameela, Rakesh Kumar Rana, Richa Singhal, Shruti Khanduri, Bhagwan Sahai Sharma, Pratap Makhija

Background: The burden of iron-deficiency anemia (IDA) remains persistently high in India due to the poor tolerability of oral iron supplementation. Therefore, more focus is required to explore traditional medicine for safe and effective options for managing IDA.

Aim: To assess the clinical safety and efficacy of Dhatri Lauha in patients with IDA.

Materials and methods: An open-label, prospective, single-arm, multi-center trial was conducted at 12 centers with a sample size of 40 participants per study site. Patients with IDA aged 18-60 years with hemoglobin levels in the range of 6-10gm/dl, mean corpuscular volume (MCV) <80 fl, mean corpuscular hemoglobin concentration (MCHC) <34 μg/dl, serum ferritin <30 μg/dl and serum iron <50 μg/dl were included in the study. Dhatri Lauha 500 mg capsule was administered twice daily with lukewarm water after meals for 45 days. The primary outcome measure was the change in hemoglobin (Hb%) level from baseline to day 45. Secondary outcome measures included the change in MCV, MCHC, serum iron and ferritin levels, incidence of adverse events, and change in safety parameters (liver and kidney function tests). The mean (statistical) change in outcome measures from baseline to day 45 was compared using a paired sample t-test.

Results: Out of 458 participants enrolled in the study, 400 contributed to the final analysis. A significant difference was observed in the outcome parameters such as Hb%, MCV, MCHC, serum ferritin, and serum iron levels (P < 0.001) after 45 days of treatment. Mean Hb% changed from 8.46 ± 1.14 g/dl at baseline to 9.18 ± 1.61 g/dl on day 45 (P < 0.001). LFT and KFT were within the normal limits after the study period. No participant withdrew from the study due to adverse events.

Conclusions: Dhatri Lauha is a safe intervention and can be expected to improve hemoglobin levels, red blood cell parameters, and iron stores in patients with IDA. Future RCTs with a larger sample size, standard care as control and a longer follow-up may produce more accurate and reliable results.

背景:由于口服补铁的耐受性较差,印度的缺铁性贫血(IDA)负担仍然很高。因此,需要更多的注意力来探索传统医学治疗IDA的安全有效的选择。目的:评估Dhatri-Lauha治疗IDA患者的临床安全性和疗效。材料和方法:在12个中心进行了一项开放标签、前瞻性、单臂、多中心的试验,每个研究点的样本量为40名参与者。年龄在18-60岁的IDA患者,血红蛋白水平在6-10gm/dl范围内,平均红细胞体积(MCV)Dhatri-Lauha 500mg胶囊每天两次,餐后用温水给药45天。主要的结果测量是从基线到第45天血红蛋白(Hb%)水平的变化。次要转归指标包括MCV、MCHC、血清铁和铁蛋白水平的变化、不良事件的发生率以及安全性参数(肝肾功能测试)的变化。使用配对样本t检验比较了从基线到第45天的结果测量的平均(统计)变化。结果:在参与该研究的458名参与者中,有400人参与了最终分析。治疗45天后,Hb%、MCV、MCHC、血清铁蛋白和血清铁水平等结果参数存在显著差异(P<0.001)。平均Hb%从基线时的8.46±1.14 g/dl变化到第45天的9.18±1.61 g/dl(P<0.001)。研究期后LFT和KFT均在正常范围内。没有参与者因不良事件退出研究。结论:Dhatri-Lauha是一种安全的干预措施,有望改善IDA患者的血红蛋白水平、红细胞参数和铁储存。未来的随机对照试验,如果样本量更大,以标准护理为对照,随访时间更长,可能会产生更准确可靠的结果。
{"title":"<i>Dhatri Lauha</i> in the management of iron deficiency anemia: A prospective open-label single-arm multi-center trial.","authors":"Narayanam Srikanth,&nbsp;Bhogavalli Chandrasekhara Rao,&nbsp;Babita Yadav,&nbsp;Amit Kumar Rai,&nbsp;Sophia Jameela,&nbsp;Rakesh Kumar Rana,&nbsp;Richa Singhal,&nbsp;Shruti Khanduri,&nbsp;Bhagwan Sahai Sharma,&nbsp;Pratap Makhija","doi":"10.4103/ayu.ayu_379_21","DOIUrl":"10.4103/ayu.ayu_379_21","url":null,"abstract":"<p><strong>Background: </strong>The burden of iron-deficiency anemia (IDA) remains persistently high in India due to the poor tolerability of oral iron supplementation. Therefore, more focus is required to explore traditional medicine for safe and effective options for managing IDA.</p><p><strong>Aim: </strong>To assess the clinical safety and efficacy of <i>Dhatri Lauha</i> in patients with IDA.</p><p><strong>Materials and methods: </strong>An open-label, prospective, single-arm, multi-center trial was conducted at 12 centers with a sample size of 40 participants per study site. Patients with IDA aged 18-60 years with hemoglobin levels in the range of 6-10gm/dl, mean corpuscular volume (MCV) <80 fl, mean corpuscular hemoglobin concentration (MCHC) <34 μg/dl, serum ferritin <30 μg/dl and serum iron <50 μg/dl were included in the study. <i>Dhatri Lauha</i> 500 mg capsule was administered twice daily with lukewarm water after meals for 45 days. The primary outcome measure was the change in hemoglobin (Hb%) level from baseline to day 45. Secondary outcome measures included the change in MCV, MCHC, serum iron and ferritin levels, incidence of adverse events, and change in safety parameters (liver and kidney function tests). The mean (statistical) change in outcome measures from baseline to day 45 was compared using a paired sample t-test.</p><p><strong>Results: </strong>Out of 458 participants enrolled in the study, 400 contributed to the final analysis. A significant difference was observed in the outcome parameters such as Hb%, MCV, MCHC, serum ferritin, and serum iron levels (<i>P</i> < 0.001) after 45 days of treatment. Mean Hb% changed from 8.46 ± 1.14 g/dl at baseline to 9.18 ± 1.61 g/dl on day 45 (<i>P</i> < 0.001). LFT and KFT were within the normal limits after the study period. No participant withdrew from the study due to adverse events.</p><p><strong>Conclusions: </strong><i>Dhatri Lauha</i> is a safe intervention and can be expected to improve hemoglobin levels, red blood cell parameters, and iron stores in patients with IDA. Future RCTs with a larger sample size, standard care as control and a longer follow-up may produce more accurate and reliable results.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/94/AYU-42-69.PMC10158651.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of nutritional value and antioxidant activity of Leea macrophylla Roxb. ex Hornem. root and leaf. 大叶李的营养价值及抗氧化活性评价。前霍纳姆。根和叶。
Ayu
Pub Date : 2021-04-01 Epub Date: 2023-03-16 DOI: 10.4103/ayu.AYU_88_19
Sarvade Dattatray Durgadas, Acharya Rabinarayan

Background: Hanshia dabar or hathkan is one of the folklore plant of Odisha, the botanical source of which is Leea macrophylla Roxb. ex Hornem., family Vitaceae. Its root and leaves are eaten as vegetables, and used for Rasayana purpose (tonic and alterative properties).

Aim: The aim is to assess the nutritive value and antioxidant potential of the root and leaves of L. macrophylla with compound leaf.

Materials and methods: Nutritional parameters such as energy value, carbohydrate, protein, true protein, fat, mineral contents, and Vitamin A, Vitamin C of the root and leaves of the plant were evaluated with standard procedures. The in vitro antioxidant properties of the root and leaf of L. macrophylla were screened through 1,1diphenyl2picrylhydrazyl (DPPH) assay, the ferric reducing antioxidant power (FRAP) assay, and phosphomolybdenum assay.

Results: Root is having higher energy value (391.87 Kcal/100 g) as compared to leaf (353.62 Kcal/100 g). L. macrophylla root and leaf showed the presence of carbohydrates (30.65% and 21.72%), protein (8.78% and 9.37%), true protein (6.85% and 7.23%), fat (0.77% and 1.89%), iron (723.80 ppm and 285.07 ppm), zinc (26.51 ppm and 13.75 ppm), manganese (44.88 ppm and 35.00 ppm), phosphorous (0.07 ppm and 0.03 ppm), calcium (7806.90 ppm and 3862.80 ppm), Vitamin A (3.63 mg/g and 2.47 mg/g), and Vitamin C (8.49 mg/g and 6.7 mg/g), respectively. Percentage scavenging of DPPH radical was found to rise with an increase in concentration. IC50 values of root and leaf, by DPPH assay, were 66.46 and 110.68 μg/ml, respectively. In the FRAP assay, the antioxidant activity of the methanolic extract of leaf (507.06 μmol/l) was found to be more than root (455.93 μmol/l). The total antioxidant capacity of root and leaf were 20.15 and 17.90 mg, equivalent to ascorbic acid on a dry weight basis, respectively.

Conclusion: Root and leaf of L. macrophylla has the highest energy value, contains carbohydrate, protein, fat, iron, zinc, manganese, phosphorous, calcium, Vitamin A, and Vitamin C, and possesses antioxidant capacity.

背景:含羞草是奥里萨邦的一种民间植物,其植物来源为大叶李。前Hornem。,维生素科。其根和叶被作为蔬菜食用,并用于Rasayana(补益和替代特性)。目的:评估具有复叶的大叶藻根和叶的营养价值和抗氧化潜力。材料和方法:采用标准程序对植物根和叶的能量值、碳水化合物、蛋白质、真蛋白、脂肪、矿物质含量以及维生素A、维生素C等营养参数进行评价。采用1,1-二苯基双芳基肼(DPPH)法、铁还原抗氧化能力(FRAP)法和磷钼法对大叶藻根和叶的体外抗氧化性能进行了筛选。结果:根的能量值(391.87千卡/100克)高于叶(353.62千卡/100 g)。L.大叶根和叶中含有碳水化合物(30.65%和21.72%)、蛋白质(8.78%和9.37%)、真蛋白(6.85%和7.23%)、脂肪(0.77%和1.89%)、铁(723.80 ppm和285.07 ppm)、锌(26.51 ppm和13.75 ppm)、锰(44.88 ppm和35.00 ppm)、磷(0.07 ppm和0.03 ppm)、钙(7806.90 ppm和3862.80 ppm)、维生素A(3.63 mg/g和2.47 mg/g),维生素C(8.49mg/g和6.7mg/g)。DPPH自由基清除率随浓度的增加而增加。DPPH法测定根和叶的IC50值分别为66.46和110.68μg/ml。在FRAP测定中,叶的甲醇提取物(507.06μmol/l)的抗氧化活性高于根(455.93μmol/l)。根和叶的总抗氧化能力分别为20.15和17.90 mg,相当于干重基础上的抗坏血酸。结论:大叶藻的根和叶具有最高的能量值,含有碳水化合物、蛋白质、脂肪、铁、锌、锰、磷、钙、维生素A和维生素C,并具有抗氧化能力。
{"title":"Evaluation of nutritional value and antioxidant activity of <i>Leea macrophylla</i> Roxb. ex Hornem. root and leaf.","authors":"Sarvade Dattatray Durgadas,&nbsp;Acharya Rabinarayan","doi":"10.4103/ayu.AYU_88_19","DOIUrl":"10.4103/ayu.AYU_88_19","url":null,"abstract":"<p><strong>Background: </strong><i>Hanshia dabar</i> or <i>hathkan</i> is one of the folklore plant of Odisha, the botanical source of which is <i>Leea macrophylla</i> Roxb. ex Hornem., family Vitaceae. Its root and leaves are eaten as vegetables, and used for <i>Rasayana</i> purpose (tonic and alterative properties).</p><p><strong>Aim: </strong>The aim is to assess the nutritive value and antioxidant potential of the root and leaves of <i>L. macrophylla</i> with compound leaf.</p><p><strong>Materials and methods: </strong>Nutritional parameters such as energy value, carbohydrate, protein, true protein, fat, mineral contents, and Vitamin A, Vitamin C of the root and leaves of the plant were evaluated with standard procedures. The <i>in vitro</i> antioxidant properties of the root and leaf of <i>L. macrophylla</i> were screened through 1,1diphenyl2picrylhydrazyl (DPPH) assay, the ferric reducing antioxidant power (FRAP) assay, and phosphomolybdenum assay.</p><p><strong>Results: </strong>Root is having higher energy value (391.87 Kcal/100 g) as compared to leaf (353.62 Kcal/100 g). <i>L. macrophylla</i> root and leaf showed the presence of carbohydrates (30.65% and 21.72%), protein (8.78% and 9.37%), true protein (6.85% and 7.23%), fat (0.77% and 1.89%), iron (723.80 ppm and 285.07 ppm), zinc (26.51 ppm and 13.75 ppm), manganese (44.88 ppm and 35.00 ppm), phosphorous (0.07 ppm and 0.03 ppm), calcium (7806.90 ppm and 3862.80 ppm), Vitamin A (3.63 mg/g and 2.47 mg/g), and Vitamin C (8.49 mg/g and 6.7 mg/g), respectively. Percentage scavenging of DPPH radical was found to rise with an increase in concentration. IC50 values of root and leaf, by DPPH assay, were 66.46 and 110.68 μg/ml, respectively. In the FRAP assay, the antioxidant activity of the methanolic extract of leaf (507.06 μmol/l) was found to be more than root (455.93 μmol/l). The total antioxidant capacity of root and leaf were 20.15 and 17.90 mg, equivalent to ascorbic acid on a dry weight basis, respectively.</p><p><strong>Conclusion: </strong>Root and leaf of <i>L. macrophylla</i> has the highest energy value, contains carbohydrate, protein, fat, iron, zinc, manganese, phosphorous, calcium, Vitamin A, and Vitamin C, and possesses antioxidant capacity.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/de/AYU-42-87.PMC10158650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telemedicine and technology: A need for the health-care system. 远程医疗和技术:对医疗保健系统的需求。
Ayu
Pub Date : 2021-04-01 Epub Date: 2023-03-16 DOI: 10.4103/ayu.ayu_5_23
Mandip Goyal
Human civilization has witnessed numerous changes to evolve itself since its inception. Every revolution that was taken either catastrophically or by gradual procedure by our ancestors themselves had evolved the generation for good, be it the straight posture of homo‐ sapiens, its colonization habits, or the human civilization itself. As every coin has both sides, despite many pitfalls, humans kept evolving themselves in pursuit of a more congenial future.
{"title":"Telemedicine and technology: A need for the health-care system.","authors":"Mandip Goyal","doi":"10.4103/ayu.ayu_5_23","DOIUrl":"10.4103/ayu.ayu_5_23","url":null,"abstract":"Human civilization has witnessed numerous changes to evolve itself since its inception. Every revolution that was taken either catastrophically or by gradual procedure by our ancestors themselves had evolved the generation for good, be it the straight posture of homo‐ sapiens, its colonization habits, or the human civilization itself. As every coin has both sides, despite many pitfalls, humans kept evolving themselves in pursuit of a more congenial future.","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/64/AYU-42-67.PMC10158653.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9486168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacognosy, phytochemistry, and molecular studies of an important medicinal herb Achillea millefolium L. 一种重要中草药千叶Achillea millefolium L.的生药学、植物化学和分子研究。
Ayu
Pub Date : 2021-04-01 Epub Date: 2023-03-16 DOI: 10.4103/ayu.ayu_401_21
Prasanna Kumar, R Shruthi, I Bindu, P Raghavendra

Background: Achillea millefolium L. is traditionally important medicinal herb used for the treatment of various ailments from the centuries. Recent studies showed its biological activities on hay fever, hepato-biliary disorders, and as appetite enhancing drug. It is also reported to be used for the treatments of skin inflammations, wounds, cuts, and abrasions.

Aim: To investigate preliminary pharmacognostical, phytochemical, and molecular parameters of aerial parts of the drug.

Materials and methods: A. millefolium was identified and collected from the Himalaya region. The material is properly dried, macro-and microscopic evaluation, phytochemical and molecular studies as per the standard quality control and WHO guidelines.

Results: The leaves are pinnately lobed, inflorescence compound corymbose. Nonglandular trichomes are uni-seriate, multicellular, and smooth walled; glandular trichomes are bicellular, present throughout the aerial parts. The endodermis is evident in the stem and leaf mesophyll is equifacial. The partial genome sequence analysis showed similarity toward studied species, which can clearly distinguish it from other species of the genus Achillea. The best chromatographic separation was observed with ascentis express C18, 2.7 μm, 100 mm × 4.6 mm. The flavonoids and phenolic acids have shown maximum absorbance at 330 nm. The system suitability parameters such as theoretical plate, tailing factor, and resolution met the acceptance criteria with United States pharmacopeia (USP).

Conclusion: The findings of this study will be helpful for the precise identification of the raw drug of A. millefolium from its closely allied species.

背景:百年来,山艾是治疗各种疾病的传统重要草药。最近的研究表明,它对花粉热、肝胆疾病和食欲增强药物具有生物学活性。据报道,它还可用于治疗皮肤炎症、伤口、割伤和擦伤。目的:初步研究该药地上部分的生药学、植物化学和分子参数。材料和方法:从喜马拉雅地区鉴定和采集了千层草。根据标准质量控制和世界卫生组织指南,对材料进行适当干燥、宏观和微观评估、植物化学和分子研究。结果:叶羽状浅裂,花序复合伞房状。非陆地毛状体是单序列的,多细胞的,和光滑的壁;腺毛是双细胞的,存在于整个地上部分。内皮层在茎部明显,叶肉等面。部分基因组序列分析显示,与所研究的物种相似,可以清楚地将其与Achillea属的其他物种区分开来。用ascentis express C18,2.7μm,100 mm×4.6 mm进行了最佳色谱分离。黄酮类化合物和酚酸在330 nm处显示出最大吸光度。系统适用性参数,如理论板、拖尾因子和分辨率,符合美国药典(USP)的验收标准。结论:本研究结果将有助于从其近缘种中准确鉴定千层草的原料药。
{"title":"Pharmacognosy, phytochemistry, and molecular studies of an important medicinal herb <i>Achillea millefolium</i> L.","authors":"Prasanna Kumar,&nbsp;R Shruthi,&nbsp;I Bindu,&nbsp;P Raghavendra","doi":"10.4103/ayu.ayu_401_21","DOIUrl":"10.4103/ayu.ayu_401_21","url":null,"abstract":"<p><strong>Background: </strong><i>Achillea</i> <i>millefolium</i> L. is traditionally important medicinal herb used for the treatment of various ailments from the centuries. Recent studies showed its biological activities on hay fever, hepato-biliary disorders, and as appetite enhancing drug. It is also reported to be used for the treatments of skin inflammations, wounds, cuts, and abrasions.</p><p><strong>Aim: </strong>To investigate preliminary pharmacognostical, phytochemical, and molecular parameters of aerial parts of the drug.</p><p><strong>Materials and methods: </strong><i>A. millefolium</i> was identified and collected from the Himalaya region. The material is properly dried, macro-and microscopic evaluation, phytochemical and molecular studies as per the standard quality control and WHO guidelines.</p><p><strong>Results: </strong>The leaves are pinnately lobed, inflorescence compound corymbose. Nonglandular trichomes are uni-seriate, multicellular, and smooth walled; glandular trichomes are bicellular, present throughout the aerial parts. The endodermis is evident in the stem and leaf mesophyll is equifacial. The partial genome sequence analysis showed similarity toward studied species, which can clearly distinguish it from other species of the genus <i>Achillea</i>. The best chromatographic separation was observed with ascentis express C18, 2.7 μm, 100 mm × 4.6 mm. The flavonoids and phenolic acids have shown maximum absorbance at 330 nm. The system suitability parameters such as theoretical plate, tailing factor, and resolution met the acceptance criteria with United States pharmacopeia (USP).</p><p><strong>Conclusion: </strong>The findings of this study will be helpful for the precise identification of the raw drug of <i>A. millefolium</i> from its closely allied species.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/8b/AYU-42-93.PMC10158652.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Punarnavadi Mandura for haematinic activity against mercuric chloride-induced anemia in albino rats. Punarnavadi Mandura对白化病大鼠氯化汞诱导的贫血的血液活性评估。
Ayu
Pub Date : 2021-04-01 Epub Date: 2023-03-16 DOI: 10.4103/ayu.AYU_294_20
V K Kori, B Ravishankar, K S Patel

Background: Punarnavadi Mandura, a compound Ayurvedic formulation, is one of the most commonly used medicine in the treatment of anemia (Pandu) in Ayurveda. The safety profile of this formulation is well established; however, no pharmacological study has been reported to provide the scientific basis for its use in the treatment of anemia.

Aim: To evaluate the hematinic effect of Punarnavadi Mandura against mercuric chloride-induced anemia in albino rats.

Materials and methods: The test drug (Punarnavadi Mandura) was suspended in distilled water and administered orally in a dose of 450 mg/kg for 30 days in rats. Anemia was induced by simultaneous administration of mercuric chloride (9 mg/kg) for 30 consecutive days. Body weight was noted for each animals. At the end, haematological parameters, anaemia markers like serum iron, ferritin, and total iron binding capacity (TIBC), as well as relative weight of organs and histopathology investigation, were examined.

Results: Exposure of mercuric chloride to rats for 30 days resulted in a significant decrease of body weight, an increase in the weight of the liver and kidney and a decrease in hemoglobin content. It also decreased serum ferritin to a significant extent and increased serum TIBC. Histopathology of the liver shows macro fatty changes, vacuolization, marked necrosis, and severe degenerative changes, while the kidney shows cell infiltration. All these changes were significantly attenuated by the administration of Punarnavadi Mandura.

Conclusion: The present data indicate that Punarnavadi Mandura has possessing marked cytoprotective activity, significantly attenuated the HgCl2-induced adverse changes on red blood cell related parameters, and showing hematinic activity in albino rats.

背景:Punarnavadi Mandura是一种复合阿育吠陀配方,是阿育吠吠陀中治疗贫血(Pandu)最常用的药物之一。该制剂的安全性已得到充分证实;然而,目前尚无药理学研究为其治疗贫血提供科学依据。目的:评价普那那那瓦地曼陀罗对氯化汞所致白化大鼠贫血的降压作用。材料和方法:试验药物(Punarnavadi Mandura)悬浮在蒸馏水中,以450 mg/kg的剂量在大鼠体内口服给药30天。通过同时给予氯化汞(9mg/kg)连续30天来诱导贫血。记录每只动物的体重。最后,检查血液学参数、贫血标志物,如血清铁、铁蛋白和总铁结合能力(TIBC),以及器官的相对重量和组织病理学研究。结果:大鼠接触氯化汞30天,体重显著下降,肝肾重量增加,血红蛋白含量下降。它还显著降低了血清铁蛋白,并增加了血清TIBC。肝脏的组织病理学显示大量脂肪变化、空泡化、明显坏死和严重退行性变化,而肾脏显示细胞浸润。结论:Punarnavadi Mandura具有显著的细胞保护活性,显著减轻了HgCl2引起的白细胞相关参数的不良变化,并在白化病大鼠中表现出降血活性。
{"title":"Evaluation of <i>Punarnavadi Mandura</i> for haematinic activity against mercuric chloride-induced anemia in albino rats.","authors":"V K Kori,&nbsp;B Ravishankar,&nbsp;K S Patel","doi":"10.4103/ayu.AYU_294_20","DOIUrl":"10.4103/ayu.AYU_294_20","url":null,"abstract":"<p><strong>Background: </strong><i>Punarnavadi</i> <i>Mandura</i>, a compound Ayurvedic formulation, is one of the most commonly used medicine in the treatment of anemia (<i>Pandu</i>) in Ayurveda. The safety profile of this formulation is well established; however, no pharmacological study has been reported to provide the scientific basis for its use in the treatment of anemia.</p><p><strong>Aim: </strong>To evaluate the hematinic effect of <i>Punarnavadi</i> <i>Mandura</i> against mercuric chloride-induced anemia in albino rats.</p><p><strong>Materials and methods: </strong>The test drug (<i>Punarnavadi</i> <i>Mandura</i>) was suspended in distilled water and administered orally in a dose of 450 mg/kg for 30 days in rats. Anemia was induced by simultaneous administration of mercuric chloride (9 mg/kg) for 30 consecutive days. Body weight was noted for each animals. At the end, haematological parameters, anaemia markers like serum iron, ferritin, and total iron binding capacity (TIBC), as well as relative weight of organs and histopathology investigation, were examined.</p><p><strong>Results: </strong>Exposure of mercuric chloride to rats for 30 days resulted in a significant decrease of body weight, an increase in the weight of the liver and kidney and a decrease in hemoglobin content. It also decreased serum ferritin to a significant extent and increased serum TIBC. Histopathology of the liver shows macro fatty changes, vacuolization, marked necrosis, and severe degenerative changes, while the kidney shows cell infiltration. All these changes were significantly attenuated by the administration of <i>Punarnavadi</i> <i>Mandura</i>.</p><p><strong>Conclusion: </strong>The present data indicate that <i>Punarnavadi</i> <i>Mandura</i> has possessing marked cytoprotective activity, significantly attenuated the HgCl<sub>2</sub>-induced adverse changes on red blood cell related parameters, and showing hematinic activity in albino rats.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/43/AYU-42-103.PMC10158649.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between Vedic personality traits (Sattva, Rajas, and Tamas) with life satisfaction and perceived stress in healthy university students: A cross-sectional study. 吠陀人格特征(Sattva、Rajas和Tamas)与健康大学生生活满意度和感知压力之间的关系:一项横断面研究。
Ayu
Pub Date : 2021-01-01 Epub Date: 2022-12-07 DOI: 10.4103/ayu.ayu_98_21
Shubham Sharma, Praerna Hemant Bhargav, Pooja Singh, Hemant Bhargav, Shivarama Varambally

Introduction: Trigunas are three basic mental attributes of a personality according to Indian Vedic literature that explains the relationship between mental attributes and human behavior. The three attributes are Tamas (tendency toward lethargy and rigidity), Rajas (tendency toward ambition and activity) and Sattva (tendency toward selfless service), respectively. Satisfaction with life and perceived stress are the important determinants of one's quality of life.

Aim: A cross-sectional study assessed the relationship between Trigunas, life satisfaction and perceived stress.

Materials and methods: The study recruited 121 willing healthy university students (75 females) with general health questionnaire scores ≤3. All participants were assessed using standardized psychometric tools.

Results: Spearman two-tailed correlation test revealed Sattva to have positive correlation with life satisfaction (r = 0.503) and negative correlation with perceived stress (r = -0.302) and other two Gunas (Tamas: R = -0.77; Rajas: R = -0.75), respectively. On the other hand, both Rajas and Tamas correlated positively with perceived stress (Rajas: R = 0.183; Tamas: R = 0.321) and negatively with life satisfaction (Rajas: R = -0.40; Tamas: R = -0.36).

Conclusion: This cross-sectional study on university students in India suggests an association of Vedic personality traits (Sattva, Rajas and Tamas Gunas) with life satisfaction, and perceived stress.

引言:根据印度吠陀文献,Trigunas是人格的三个基本心理属性,该文献解释了心理属性与人类行为之间的关系。这三种特质分别是Tamas(无精打采和僵硬的倾向)、Rajas(雄心勃勃和活跃的倾向)和Sattva(无私服务的倾向)。对生活的满意度和感知到的压力是一个人生活质量的重要决定因素。目的:一项横断面研究评估了Trigunas、生活满意度和感知压力之间的关系。材料和方法:本研究招募了121名有意愿的健康大学生(75名女性),其一般健康问卷得分≤3。所有参与者均使用标准化心理测量工具进行评估。结果:Spearman双尾相关检验显示,Sattva与生活满意度呈正相关(r=0.503),与感知压力呈负相关(r=-0.302),与其他两种Gunas呈正相关(Tamas:r=-0.77;Rajas:r=-0.75)。另一方面,Rajas和Tamas与感知压力呈正相关(Rajas:R=0.183;Tamas:R=0.321),与生活满意度呈负相关(Rajast:R=-0.40;Tamas:R=-0.36)。
{"title":"Relationship between <i>Vedic</i> personality traits (<i>Sattva, Rajas</i>, and <i>Tamas</i>) with life satisfaction and perceived stress in healthy university students: A cross-sectional study.","authors":"Shubham Sharma,&nbsp;Praerna Hemant Bhargav,&nbsp;Pooja Singh,&nbsp;Hemant Bhargav,&nbsp;Shivarama Varambally","doi":"10.4103/ayu.ayu_98_21","DOIUrl":"10.4103/ayu.ayu_98_21","url":null,"abstract":"<p><strong>Introduction: </strong><i>Trigunas</i> are three basic mental attributes of a personality according to Indian <i>Vedic</i> literature that explains the relationship between mental attributes and human behavior. The three attributes are <i>Tamas</i> (tendency toward lethargy and rigidity), <i>Rajas</i> (tendency toward ambition and activity) and <i>Sattva</i> (tendency toward selfless service), respectively. Satisfaction with life and perceived stress are the important determinants of one's quality of life.</p><p><strong>Aim: </strong>A cross-sectional study assessed the relationship between <i>Trigunas</i>, life satisfaction and perceived stress.</p><p><strong>Materials and methods: </strong>The study recruited 121 willing healthy university students (75 females) with general health questionnaire scores ≤3. All participants were assessed using standardized psychometric tools.</p><p><strong>Results: </strong>Spearman two-tailed correlation test revealed <i>Sattva</i> to have positive correlation with life satisfaction (<i>r</i> = 0.503) and negative correlation with perceived stress (<i>r</i> = -0.302) and other two <i>Gunas</i> (<i>Tamas</i>: <i>R</i> = -0.77; <i>Rajas</i>: <i>R</i> = -0.75), respectively. On the other hand, both <i>Rajas</i> and <i>Tamas</i> correlated positively with perceived stress (<i>Raja</i>s: <i>R</i> = 0.183; <i>Tamas</i>: <i>R</i> = 0.321) and negatively with life satisfaction (<i>Rajas</i>: <i>R</i> = -0.40; <i>Tamas</i>: <i>R</i> = -0.36).</p><p><strong>Conclusion: </strong>This cross-sectional study on university students in India suggests an association of <i>Vedic</i> personality traits (<i>Sattva, Rajas</i> and <i>Tamas Gunas</i>) with life satisfaction, and perceived stress.</p>","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/ab/AYU-42-39.PMC9893901.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10663210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Ayu
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1